– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) –…
Read More
– Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter – Second development program, ADMIR, continues to advance with first-in-humanclinical trial expected to…
– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage…
– Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants – Company’s abuse-deterrent stimulant formulations have the potential…
PHILADELPHIA, PA, Jan. 04, 2022 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed…
– Topline results from pivotal SEAL study expected in Q1 2022 – If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA,…
– Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 – Advancement of second development program, ADMIR, with selection…
– Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov….
– Live video webcast presentation on Monday, November 15th at 8:30 am ET PHILADELPHIA, PA, Nov. 10, 2021 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage…
– Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication – Company’s lead…
